{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:17:11Z","timestamp":1791069431343,"version":"4.1.0"},"reference-count":246,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Lipid Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.plipres.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T17:26:24Z","timestamp":1528133184000},"page":"54-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["High density lipoprotein cholesterol and cancer: Marker or causative?"],"prefix":"10.1016","volume":"71","author":[{"given":"Matteo","family":"Pirro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plipres.2018.06.001_bb0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.plipres.2012.03.003","article-title":"Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?","volume":"51","author":"Otocka-Kmiecik","year":"2012","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1053\/meta.2003.50072","article-title":"Plasma C-reactive protein in subjects with hypo\/hyperalphalipoproteinemias","volume":"52","author":"Pirro","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.plipres.2018.06.001_bb0015","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0026-0495(03)00157-4","article-title":"Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia","volume":"52","author":"Lupattelli","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.plipres.2018.06.001_bb0020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0002-9149(02)02575-4","article-title":"Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia","volume":"90","author":"Lupattelli","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/cvr\/cvu150","article-title":"HDL in innate and adaptive immunity","volume":"103","author":"Catapano","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.beem.2013.11.001","article-title":"Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality","volume":"28","author":"Barylski","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.plipres.2018.06.001_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14656566.2016.1129402","article-title":"Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?","volume":"17","author":"Page","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.plipres.2018.06.001_bb0040","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.plipres.2018.06.001_bb0045","first-page":"643","article-title":"Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study","volume":"38","author":"Penson","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.plipres.2018.06.001_bb0050","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1038\/srep09495","article-title":"Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis","volume":"5","author":"Yang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2018.06.001_bb0055","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.jacc.2009.12.069","article-title":"Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy","volume":"55","author":"Jafri","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0060","doi-asserted-by":"crossref","first-page":"823849","DOI":"10.1155\/2013\/823849","article-title":"Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses","volume":"2013","author":"Melvin","year":"2013","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1055-9965.EPI-14-1329","article-title":"Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies","volume":"24","author":"YuPeng","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0070","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1017\/S1368980015000646","article-title":"The association between serum lipids and colorectal neoplasm: a systemic review and meta-analysis","volume":"18","author":"Tian","year":"2015","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.plipres.2018.06.001_bb0075","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/bjc.1981.94","article-title":"Peculiarities of hyperlipidaemia in tumour patients","volume":"43","author":"Dilman","year":"1981","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0080","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(82)90543-5","article-title":"Plasma lipid alterations in leukemia and lymphoma","volume":"72","author":"Spiegel","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2796.1993.tb00674.x","article-title":"The acute phase response and associated lipoprotein abnormalities accompanying lymphoma","volume":"233","author":"Blackman","year":"1993","journal-title":"J Intern Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjc.1992.361","article-title":"Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130)","volume":"66","author":"Dess\u00ed","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1749-6632.1993.tb38731.x","article-title":"Metabolic determinants of low HDL-C levels","volume":"676","author":"Breslow","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.plipres.2018.06.001_bb0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2478\/s11658-008-0014-9","article-title":"Lipid changes occurring in the course of hematological cancers","volume":"13","author":"Kuliszkiewicz-Janus","year":"2008","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.plipres.2018.06.001_bb0105","first-page":"466","article-title":"Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging","volume":"15","author":"Mooberry","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0029-1241859","article-title":"Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue","volume":"42","author":"Schimanski","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-09665-0_1","article-title":"Structure of HDL: particle subclasses and molecular components","volume":"224","author":"Kontush","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbalip.2010.11.003","article-title":"Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry","volume":"1811","author":"Scherer","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.plipres.2018.06.001_bb0125","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.chroma.2010.01.006","article-title":"Profiling of phospholipids in lipoproteinsby multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry","volume":"1217","author":"Lee","year":"2010","journal-title":"J Chromatogr"},{"key":"10.1016\/j.plipres.2018.06.001_bb0130","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1194\/jlr.M006494","article-title":"Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol","volume":"51","author":"Yetukuri","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0135","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0140","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1194\/jlr.M500531-JLR200","article-title":"Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I","volume":"47","author":"Duong","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein. A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0150","doi-asserted-by":"crossref","first-page":"31532","DOI":"10.1038\/srep31532","article-title":"Bioinformatics analysis of plasma Apolipoproteins A-I and A-II revealed unique features of A-I\/A-II HDL particles in human plasma","volume":"6","author":"Kido","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2018.06.001_bb0155","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/pmic.200401010","article-title":"Mapping of proteins in high density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry","volume":"5","author":"Karlsson","year":"2005","journal-title":"Proteomics"},{"issue":"6","key":"10.1016\/j.plipres.2018.06.001_bb0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pmic.200500191","article-title":"Proteomic analysis of high density lipoprotein","author":"Rezaee","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.plipres.2018.06.001_bb0165","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbrc.2005.12.098","article-title":"Diverse range of small peptides associated with high-density lipoprotein","volume":"340","author":"Hortin","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2018.06.001_bb0170","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M704590200","article-title":"Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles","volume":"282","author":"Vedhachalam","year":"2007","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.plipres.2018.06.001_bb0175","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nsmb.2028","article-title":"Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma","volume":"18","author":"Huang","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0180","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-2275(20)32028-9","article-title":"Apolipoprotein A-I: structure\u2013function relationships","volume":"41","author":"Frank","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0185","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","article-title":"High density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase","volume":"7","author":"Yuhanna","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0021-9150(01)00447-6","article-title":"The impact of phospholipid transfer protein (PLTP) on HDL metabolism","volume":"155","author":"Huuskonen","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0195","doi-asserted-by":"crossref","first-page":"21090","DOI":"10.1074\/jbc.M701228200","article-title":"Steroid regulator element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status","volume":"282","author":"Tamehiro","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2018.06.001_bb0200","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/ATVBAHA.111.238360","article-title":"HNF4\u03b1 increases liver-specific human ATP-binding cassette transporter A1 expression and cholesterol efflux to apolipoprotein A-I in response to cholesterol depletion","volume":"32","author":"Ohoka","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0205","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1073\/pnas.89.21.10316","article-title":"High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors","volume":"89","author":"Bowry","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.plipres.2018.06.001_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(98)00173-7","article-title":"Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis","volume":"141","author":"Heinecke","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0215","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-2275(20)33461-1","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-5793(03)00261-8","article-title":"Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells","volume":"540","author":"Sacre","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.plipres.2018.06.001_bb0225","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1006\/bbrc.2000.2877","article-title":"High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis","volume":"272","author":"Sugano","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2018.06.001_bb0230","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti- and pro-apoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of HDL-proteome remodeling","volume":"127","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.plipres.2018.06.001_bb0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12944-017-0429-2","article-title":"HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium","volume":"16","author":"Ruiz","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0240","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/CIRCRESAHA.111.258673","article-title":"Novel biological functions of high-density lipoprotein cholesterol","volume":"111","author":"Mineo","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0245","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/1055-9965.EPI-08-1248","article-title":"Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer","volume":"18","author":"Ahn","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0250","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3945\/ajcn.115.124321","article-title":"Lipid biomarkers and long-term risk of cancer in the Women's Health Study","volume":"103","author":"Chandler","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.plipres.2018.06.001_bb0255","doi-asserted-by":"crossref","first-page":"e4434","DOI":"10.1097\/MD.0000000000004434","article-title":"Ad. Monforte, ICONA Foundation Study Group, High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort","volume":"95","author":"Squillace","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.plipres.2018.06.001_bb0260","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.2337\/dc14-0523","article-title":"HDL cholesterol and cancer risk among patients with type 2 diabetes","volume":"37","author":"Zhao","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.plipres.2018.06.001_bb0265","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1038\/srep09495","article-title":"Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis","volume":"5","author":"Yang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.plipres.2018.06.001_bb0270","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.plipres.2018.06.001_bb0275","first-page":"107","article-title":"Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points","author":"Martin","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.plipres.2018.06.001_bb0280","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jnci\/82.6.460","article-title":"Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer","volume":"82","author":"Boyd","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.plipres.2018.06.001_bb0285","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S000711451500183X","article-title":"Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies","volume":"114","author":"Touvier","year":"2015","journal-title":"Br J Nutr"},{"key":"10.1016\/j.plipres.2018.06.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142669","article-title":"Serum Lipids and Breast Cancer Risk: A Meta-Analysis of Prospective Cohort Studies","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb0295","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.annepidem.2008.06.006","article-title":"HDL-cholesterol and incidence of breast cancer in the ARIC cohort study","volume":"18","author":"Kucharska-Newton","year":"2008","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0300","first-page":"483","article-title":"Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status","volume":"7","author":"Moorman","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0305","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.7314\/APJCP.2012.13.7.3385","article-title":"Assessment of biochemical profiles in premenopausal and postmenopausal women with breast cancer","volume":"13","author":"Yadav","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11010-005-2993-4","article-title":"Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer","volume":"268","author":"Michalaki","year":"2005","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.plipres.2018.06.001_bb0315","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1055-9965.33.14.1","article-title":"Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study","volume":"14","author":"Furberg","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0320","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1055-9965.EPI-08-0133","article-title":"Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea","volume":"18","author":"Kim","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0325","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/djh216","article-title":"Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk","volume":"96","author":"Furberg","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.plipres.2018.06.001_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2016.11.024","article-title":"The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer","volume":"32","author":"Li","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.plipres.2018.06.001_bb0335","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.5301\/jbm.5000143","article-title":"Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs","volume":"26","author":"Fan","year":"2015","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.plipres.2018.06.001_bb0340","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12885-017-3232-6","article-title":"Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort","volume":"17","author":"Melvin","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0345","first-page":"77","article-title":"Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study","volume":"28","author":"His","year":"2017","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.plipres.2018.06.001_bb0350","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2016.11.033","article-title":"VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis","volume":"388","author":"Lu","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.plipres.2018.06.001_bb0355","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-291X(85)91847-9","article-title":"Interaction of estradiol and high density lipoproteins on proliferation of the human breast cancer cell line MCF-7 adapted to grow in serum free conditions","volume":"133","author":"Jozan","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2018.06.001_bb0360","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ijc.2910430523","article-title":"Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines","volume":"43","author":"Rotheneder","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0365","first-page":"3704","article-title":"High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium","volume":"42","author":"Gospodarowicz","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0370","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1078-0432.CCR-11-0817","article-title":"HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis","volume":"18","author":"Pan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0375","first-page":"122","article-title":"Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study","volume":"3","author":"Seth","year":"2012","journal-title":"Int J Mol Epidemiol Genet"},{"key":"10.1016\/j.plipres.2018.06.001_bb0380","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1677\/ERC-07-0132","article-title":"Metabolic syndrome, plasmalipid, lipoprotein andglucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"14","author":"Cust","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0385","first-page":"158","article-title":"Plasma lipid profile in gynecologic cancers","volume":"29","author":"Qadir","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0390","first-page":"348","article-title":"Serum lipid profile in gynecologic tumors: a retrospective clinical study of 1,550 patients","volume":"37","author":"Sun","year":"2016","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0395","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/ijc.30818","article-title":"The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort","volume":"141","author":"Nderitu","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0400","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12944-017-0509-3","article-title":"A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections","volume":"16","author":"Tian","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0405","first-page":"1259","article-title":"Hypercholesterolemia and prostate cancer: a hospital-based case-control study","volume":"19","author":"Magura","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.plipres.2018.06.001_bb0410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/13685530903410617","article-title":"Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer","volume":"13","author":"Grosman","year":"2010","journal-title":"Aging Male"},{"key":"10.1016\/j.plipres.2018.06.001_bb0415","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.ejca.2005.09.003","article-title":"Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer","volume":"41","author":"Hammarsten","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0420","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08037050310025735","article-title":"Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer","volume":"13","author":"Hammarsten","year":"2004","journal-title":"Blood Press"},{"key":"10.1016\/j.plipres.2018.06.001_bb0425","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4103\/0970-1591.74440","article-title":"Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive crosssectional study","volume":"26","author":"Prabhat","year":"2010","journal-title":"Indian J Urol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0430","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12944-015-0096-0","article-title":"Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men","volume":"14","author":"Salgado-Montilla","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0435","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.12659\/MSM.893442","article-title":"Metabolic Syndrome Components are Associated with Increased Prostate Cancer Risk","volume":"21","author":"Zhang","year":"2015","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.plipres.2018.06.001_bb0440","first-page":"1905","article-title":"Role of hypercholesterolemia in prostate cancer\u2014case control study from Manipal Teaching Hospital Pokhara, Nepal, Asian. Pac","volume":"12","author":"Mittal","year":"2011","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0445","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/1055-9965.EPI-06-0777","article-title":"Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer","volume":"16","author":"Tuohimaa","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0450","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/1055-9965.EPI-08-1248","article-title":"Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer","volume":"18","author":"Ahn","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0455","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/pcan.2011.30","article-title":"Blood lipid levels and prostate cancer risk; a cohort study","volume":"14","author":"Kok","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0460","first-page":"1181","article-title":"Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway","volume":"20","author":"Martin","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.plipres.2018.06.001_bb0465","first-page":"1313","article-title":"Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry","volume":"28","author":"Tulloch-Reid","year":"2017","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.plipres.2018.06.001_bb0470","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/1055-9965.EPI-14-0458","article-title":"Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database","volume":"23","author":"Allott","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0475","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/cam4.695","article-title":"Blood lipids and prostate cancer: a Mendelian randomization analysis","volume":"5","author":"Bull","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0480","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/aje\/kwv294","article-title":"Blood lipid concentrations and colorectal adenomas: a systematic review and meta-analysis of colonoscopy studies in Asia, 2000\u20132014","volume":"183","author":"Passarelli","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0485","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12029-014-9671-2","article-title":"Ethnic disparities in the risk of colorectal adenomas associated with lipid levels: a retrospective multiethnic study","volume":"46","author":"Davis-Yadley","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0490","first-page":"635","article-title":"Plasma lipid levels and colorectal adenoma risk","volume":"26","author":"Coppola","year":"2015","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.plipres.2018.06.001_bb0495","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/gut.2010.225011","article-title":"Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition","volume":"60","author":"van Duijnhoven","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.plipres.2018.06.001_bb0500","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-230X-10-51","article-title":"Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0505","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.3748\/wjg.v20.i26.8646","article-title":"Lipid levels in serum and cancerous tissues of colorectal cancer patients","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0510","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.2147\/OTT.S90479","article-title":"A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C","volume":"8","author":"Liao","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.plipres.2018.06.001_bb0515","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/ijc.30709","article-title":"Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer","volume":"140","author":"Rodriguez-Broadbent","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0520","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.bjc.6604047","article-title":"Gallstones and the risk of biliary tract cancer: a population-based study in China","volume":"97","author":"Hsing","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0525","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/ijc.23307","article-title":"Serum lipid levels and the risk of biliary tract cancers and biliary stones: a population-based study in China","volume":"122","author":"Andreotti","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0530","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/BF00235527","article-title":"The relationship between serum lipids, nucleation time, and biliary lipids in patients with gallstones","volume":"70","author":"Janowitz","year":"1992","journal-title":"Clin Investig"},{"key":"10.1016\/j.plipres.2018.06.001_bb0535","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0676.1993.tb00639.x","article-title":"Bile and plasma lipid composition in non-obese normolipidemic subjects with and without cholesterol gallstones","volume":"13","author":"Halpern","year":"1993","journal-title":"Liver"},{"key":"10.1016\/j.plipres.2018.06.001_bb0540","first-page":"461","article-title":"Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma","volume":"9","author":"Lv","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.plipres.2018.06.001_bb0545","doi-asserted-by":"crossref","first-page":"e91080","DOI":"10.1371\/journal.pone.0091080","article-title":"High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma","volume":"9","author":"Chi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb0550","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1159\/000227088","article-title":"Altered pattern of lipid metabolism in patients with lung cancer","volume":"49","author":"Dessi","year":"1992","journal-title":"Oncology"},{"key":"10.1016\/j.plipres.2018.06.001_bb0555","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s005990070013","article-title":"Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects","volume":"30","author":"Fiorenza","year":"2000","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0560","first-page":"307","article-title":"Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer","volume":"6","author":"Siemianowicz","year":"2000","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0565","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.lungcan.2008.01.015","article-title":"HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study","volume":"61","author":"Kucharska-Newton","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0570","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacl.2017.05.004","article-title":"Blood lipids profile and lung cancer risk in a meta-analysis of prospective cohort studies","volume":"11","author":"Lin","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0575","first-page":"461","article-title":"Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma","volume":"9","author":"Lv","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.plipres.2018.06.001_bb0580","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ijc.30581","article-title":"Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations","volume":"140","author":"Zhang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0585","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/CBM-150544","article-title":"High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients","volume":"16","author":"Lv","year":"2016","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.plipres.2018.06.001_bb0590","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1158\/0008-5472.CAN-07-0212","article-title":"Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma","volume":"67","author":"Lim","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0595","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s13277-013-1284-z","article-title":"Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer\/T cell lymphoma","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0600","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fphar.2013.00119","article-title":"The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics","volume":"4","author":"Cruz","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0605","doi-asserted-by":"crossref","first-page":"21237","DOI":"10.1074\/jbc.M113.468967","article-title":"The cardioprotective protein apolipoprotein A1 promotes potent antitumorigenic effects","volume":"288","author":"Zamanian-Daryoush","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2018.06.001_bb0610","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3892\/or.2014.3277","article-title":"Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer","volume":"32","author":"Cine","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.plipres.2018.06.001_bb0615","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1515\/CCLM.2007.263","article-title":"The association between lipid profiles and breast cancer among Taiwanese women","volume":"45","author":"Chang","year":"2007","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0620","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10654-014-9884-5","article-title":"Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk","volume":"29","author":"His","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0625","first-page":"247","article-title":"Plasma apolipoprotein A1 levels at diagnosis are independent prognostic factors in invasive ductal breast cancer","volume":"23","author":"Lin","year":"2017","journal-title":"Discov Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0630","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/ENDO:26:1:019","article-title":"Serum levels of leptin, insulin, and lipids in relation to breast cancer in china","volume":"26","author":"Han","year":"2005","journal-title":"Endocrine"},{"key":"10.1016\/j.plipres.2018.06.001_bb0635","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12944-016-0225-4","article-title":"Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer","volume":"15","author":"Flote","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0640","first-page":"330","article-title":"The dyslipidemia-associated SNP on the APOA1\/C3\/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study, BMC","volume":"13","author":"Hsu","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0645","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s11033-010-0274-0","article-title":"Apolipoprotein A1 -75 G\/A and +83 C\/T polymorphisms: susceptibility and prognostic implications in breast cancer","volume":"38","author":"Hamrita","year":"2011","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.plipres.2018.06.001_bb0650","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12032-014-0407-8","article-title":"Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer","volume":"32","author":"Cheng","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0655","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1074\/mcp.M113.031252","article-title":"Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients","volume":"12","author":"Mustafa","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.plipres.2018.06.001_bb0660","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12032-012-0420-8","article-title":"High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques","volume":"30","author":"Qin","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0665","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1309\/AJCPD8NBSHXRXQL7","article-title":"APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival","volume":"142","author":"Stavnes","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0670","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bjc.2012.14","article-title":"Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection","volume":"106","author":"Nunes","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0675","first-page":"268","article-title":"Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation","volume":"37","author":"Sing","year":"1985","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.plipres.2018.06.001_bb0680","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1042\/CS20020329","article-title":"Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis","volume":"104","author":"Watson","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.plipres.2018.06.001_bb0685","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/carcin\/bgi088","article-title":"Associations between apoE genotype and colon and rectal cancer","volume":"26","author":"Slattery","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0690","first-page":"707","article-title":"Apolipoprotein E Genotypes in Patients with Prostate Cancer","volume":"36","author":"Yencilek","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0695","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1054\/bjoc.2001.2098","article-title":"The apolipoprotein E epsilon4 allele is no risk factor for prostate cancer in the Norwegian population","volume":"85","author":"Wessel","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0700","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/bjc.1998.695","article-title":"Possible relationship of the apolipoprotein E (ApoE) epsilon4 allele to prostate cancer","volume":"78","author":"Lehrer","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0705","first-page":"189","article-title":"A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor","volume":"30","author":"Grant","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0710","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2010.04.009","article-title":"Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer","volume":"71","author":"Su","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0715","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MOL.0b013e328304b64e","article-title":"Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?","volume":"19","author":"Reddy","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0720","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1055-9965.EPI-05-0930","article-title":"Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II nutrition cohort","volume":"15","author":"Stevens","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0725","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/95.11.812","article-title":"New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men","volume":"95","author":"Marchesani","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.plipres.2018.06.001_bb0730","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1074\/mcp.M113.028621","article-title":"Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer","volume":"13","author":"Ahn","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.plipres.2018.06.001_bb0735","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2310\/JIM.0b013e318245d557","article-title":"Association of genetic polymorphisms in the paraoxonase 1 gene with the risk and prognosis of non-small cell lung cancer in Chinese Han population","volume":"60","author":"Wang","year":"2012","journal-title":"J Invest Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119100","article-title":"Interactions between paraoxonase 1 genetic polymorphisms and smoking and their effects on oxidative stress and lung cancer risk in a Korean population","volume":"10","author":"Eom","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb0745","first-page":"2225","article-title":"Paraoxonase-1 192\/55 polymorphisms and the risk of lung cancer in a Turkish population","volume":"31","author":"Aksoy-Sagirli","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0750","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jcla.21503","article-title":"Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer","volume":"26","author":"Balci","year":"2012","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.plipres.2018.06.001_bb0755","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/abbs\/gms055","article-title":"Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients","volume":"44","author":"Sun","year":"2012","journal-title":"Acta Biochim Biophys Sin"},{"key":"10.1016\/j.plipres.2018.06.001_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173385","article-title":"Human paraoxonase 1 overexpression in mice stimulates HDL cholesterol efflux and reverse cholesterol transport","volume":"12","author":"Ikhlef","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb0765","first-page":"368","article-title":"Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients, Kaohsiung","volume":"29","author":"Eroglu","year":"2013","journal-title":"J Med Sci"},{"key":"10.1016\/j.plipres.2018.06.001_bb0770","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.7314\/APJCP.2015.16.10.4457","article-title":"Paraoxonase 1 (PON1) Q192R Gene Polymorphism and Cancer Risk: A Meta-Analysis Based on 30 Publications","volume":"16","author":"Zhang","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0775","first-page":"1151","article-title":"Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.plipres.2018.06.001_bb0780","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pros.20184","article-title":"Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer","volume":"63","author":"Antognelli","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.plipres.2018.06.001_bb0785","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/pros.20796","article-title":"Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort","volume":"68","author":"Stevens","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.plipres.2018.06.001_bb0790","doi-asserted-by":"crossref","first-page":"e74014","DOI":"10.1371\/journal.pone.0074014","article-title":"Glyoxalase 1-419C.A variant is associated with oxidative stress: implications in prostate cancer progression","volume":"8","author":"Antognelli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb0795","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5152\/tud.2017.74151","article-title":"A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer","volume":"43","author":"Uluocak","year":"2017","journal-title":"Turk J Urol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0800","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s13277-015-4141-4","article-title":"High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer","volume":"37","author":"Yuan","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0805","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-03-0675","article-title":"A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells","volume":"64","author":"Cao","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0810","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1186\/s12958-015-0087-z","article-title":"The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence","volume":"13","author":"Sch\u00f6rghofer","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0815","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1200\/JCO.2008.18.9068","article-title":"Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients","volume":"27","author":"Pierce","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0820","doi-asserted-by":"crossref","first-page":"35843","DOI":"10.18632\/oncotarget.8561","article-title":"Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.plipres.2018.06.001_bb0825","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2008.01.079","article-title":"Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer","volume":"368","author":"Michaeli","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.plipres.2018.06.001_bb0830","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1369\/jhc.5A6645.2005","article-title":"Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis","volume":"54","author":"Gutfeld","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.plipres.2018.06.001_bb0835","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.7314\/APJCP.2014.15.24.10713","article-title":"Serum amyloid A is a novel prognostic biomarker in hepatocellular carcinoma, Asian","volume":"15","author":"Ni","year":"2014","journal-title":"Pac J Cancer Prev"},{"key":"10.1016\/j.plipres.2018.06.001_bb0840","first-page":"9","article-title":"Expression of serum amyloid A in uterine cervical cancer","volume":"21","author":"Ren","year":"2014","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0845","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1369\/jhc.2010.956821","article-title":"Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis","volume":"58","author":"Urieli-Shoval","year":"2010","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.plipres.2018.06.001_bb0850","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cncr.24838","article-title":"Serum amyloid A: a novel biomarker for endometrial cancer","volume":"116","author":"Cocco","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0855","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjc.6605129","article-title":"Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer","volume":"101","author":"Cocco","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0860","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1186\/s12885-016-2882-0","article-title":"Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies","volume":"16","author":"Biaoxue","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0865","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-006-9175-2","article-title":"Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients","volume":"99","author":"Park","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.plipres.2018.06.001_bb0870","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0029-1241859","article-title":"Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue","volume":"42","author":"Schimanski","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0875","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3892\/etm.2017.4393","article-title":"ABCG1 as a potential oncogene in lung cancer","volume":"13","author":"Tian","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0880","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/ncomms7354","article-title":"The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity","volume":"6","author":"Sag","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.plipres.2018.06.001_bb0885","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/ijc.29991","article-title":"Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients","volume":"138","author":"Wang","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0890","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/s12885-015-1689-8","article-title":"Frequent down-regulation of ABC transporter genes in prostate cancer","volume":"15","author":"Demidenko","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb0895","first-page":"106","article-title":"ABCA transporter gene expression and poor outcome in epithelial ovarian cancer","author":"Hedditch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.plipres.2018.06.001_bb0900","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1194\/jlr.M000323","article-title":"Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2)","volume":"51","author":"Annema","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0905","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1194\/jlr.R004739","article-title":"Genetic causes of high and low serum HDL-cholesterol","volume":"51","author":"Weissglas-Volkov","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0910","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MOL.0000000000000333","article-title":"Effect of inflammation on HDL structure and function","volume":"27","author":"Feingold","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0915","author":"Carroll"},{"key":"10.1016\/j.plipres.2018.06.001_bb0920","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.pathol.2017.03.011","article-title":"Extremely low high-density lipoprotein cholesterol (HDL) in a patient with diffuse B-cell lymphoma","volume":"49","author":"Loh","year":"2017","journal-title":"Pathology"},{"key":"10.1016\/j.plipres.2018.06.001_bb0925","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185307","article-title":"Combining LDL-C and HDL-C to predict survival in late life: The InChianti study","volume":"12","author":"Zuliani","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb0930","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study","volume":"68","author":"Ko","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0935","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The Framingham Heart Study","volume":"8","author":"Wilson","year":"1998","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.plipres.2018.06.001_bb0940","doi-asserted-by":"crossref","first-page":"e000519","DOI":"10.1161\/JAHA.113.000519","article-title":"Coronary heart disease risks associated with high levels of HDL cholesterol","volume":"vol. 3","author":"Wilkins","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.plipres.2018.06.001_bb0945","unstructured":"K.R. Feingold, C. Grunfeld, The effect of inflammation and infection on lipids and lipoproteins, in: L.J. DeGroot, P. Beck-Peccoz, G. Chrousos, K. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik, (Eds.). Endotext, South Dartmouth, 2000\u20132015."},{"key":"10.1016\/j.plipres.2018.06.001_bb0950","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.plipres.2018.06.001_bb0955","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","article-title":"Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host","volume":"45","author":"Khovidhunkit","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0960","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1097\/01.CCM.0000171183.79525.6B","article-title":"Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis","volume":"33","author":"Chien","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb0965","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4414\/smw.2009.12494","article-title":"Prognostic impact of plasma lipids in patients with lower respiratory tract infections \u2013 an observational study","volume":"139","author":"Gruber","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.plipres.2018.06.001_bb0970","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jcrc.2014.04.018","article-title":"Serum lipid profile, cytokine production, and clinical outcome in patients with severe sepsis","volume":"29","author":"Lekkou","year":"2014","journal-title":"J Crit Care"},{"key":"10.1016\/j.plipres.2018.06.001_bb0975","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1021\/bi0518040","article-title":"Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK\/ERK and JNK signaling","volume":"45","author":"Beers","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.plipres.2018.06.001_bb0980","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jcb.24656","article-title":"Inhibition of apolipoprotein A-I expression by TNF-alpha in HepG2 cells: requirement for c-jun","volume":"115","author":"Parseghian","year":"2014","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.plipres.2018.06.001_bb0985","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1194\/jlr.M017681","article-title":"Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase","volume":"52","author":"Wroblewski","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb0990","first-page":"1","article-title":"Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states","volume":"8","author":"Vadas","year":"1993","journal-title":"J Lipid Mediat"},{"key":"10.1016\/j.plipres.2018.06.001_bb0995","doi-asserted-by":"crossref","first-page":"10077","DOI":"10.1074\/jbc.275.14.10077","article-title":"Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I","volume":"275","author":"Tietge","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2018.06.001_bb1000","doi-asserted-by":"crossref","first-page":"10011","DOI":"10.1074\/jbc.M113.525717","article-title":"Proteolysis of apolipoprotein A-I by secretory phospholipase A(2): a new link between inflammation and atherosclerosis","volume":"289","author":"Cavigiolio","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.plipres.2018.06.001_bb1005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MOL.0000000000000333","article-title":"Effect of inflammation on HDL structure and function","volume":"27","author":"Feingold","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/2047487314538858","article-title":"Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis","volume":"22","author":"Pirro","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2018.06.001_bb1020","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ypmed.2003.12.002","article-title":"Acute exposure to environmental tobacco smoke reduces HDL-C and HDL2-C","volume":"38","author":"Moffatt","year":"2004","journal-title":"Prev Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.59566\/IJBS.2017.13020","article-title":"Tobacco smoke exposure reduces paraoxonase activity in a murine model","volume":"13","author":"Reed","year":"2017","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.plipres.2018.06.001_bb1030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3109\/08958378.2014.965559","article-title":"Cigarette smoking is associated with dose-dependent adverse effects on paraoxonase activity and fibrinogen in young women","volume":"26","author":"Ramanathan","year":"2014","journal-title":"Inhal Toxicol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1035","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-12-0324","article-title":"Insulin resistance and cancer: the role of insulin and IGFs","volume":"20","author":"Djiogue","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb1040","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40618-016-0508-7","article-title":"Insulin, insulin receptors, and cancer","volume":"39","author":"Vigneri","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.plipres.2018.06.001_bb1045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1874192401105010035","article-title":"Malignancy-associated dyslipidemia","volume":"5","author":"Bielecka-D\u0105browa","year":"2011","journal-title":"Open Cardiovasc Med J"},{"key":"10.1016\/j.plipres.2018.06.001_bb1050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb1055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"STELLAR study group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9149(02)02994-6","article-title":"Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease","volume":"91","author":"Schneck","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1065","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(03)00003-1","article-title":"Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups","volume":"91","author":"Blasetto","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1067\/mhj.2002.129312","article-title":"Rosuvastatin Study Group, Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial","volume":"144","author":"Brown","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.plipres.2018.06.001_bb1075","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1007\/s13277-015-3551-7","article-title":"The effect of statins on cancer cells\u2014review","volume":"36","author":"Matusewicz","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1080","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-014-0309-2","article-title":"Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes?","volume":"74","author":"Bonovas","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.plipres.2018.06.001_bb1085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2014.06.013","article-title":"Novel prospects of statins as therapeutic agents in cancer","volume":"88","author":"Pisanti","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb1090","first-page":"413","article-title":"Statins as anti-cancer therapy; can we translate preclinical and epidemiologic data into clinical benefit?","volume":"20","author":"Chae","year":"2015","journal-title":"Discov Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1095","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","article-title":"Fibrates, glitazones, and peroxisome proliferator-activated receptors","volume":"30","author":"Lalloyer","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1100","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1517\/14656566.2014.972365","article-title":"Fibrates and niacin: is there a place for them in clinical practice?","volume":"15","author":"Wierzbicki","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.plipres.2018.06.001_bb1105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate","volume":"40","author":"WHO Cooperative Trial Committee of Principal Investigators","year":"1978","journal-title":"Br Heart J"},{"key":"10.1016\/j.plipres.2018.06.001_bb1110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.1996.03530250059028","article-title":"Carcinogenicity of lipid-lowering drugs","volume":"275","author":"Newman","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.plipres.2018.06.001_bb1115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.1996.03530250071030","article-title":"Does lowering cholesterol cause cancer?","volume":"275","author":"Dalen","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.plipres.2018.06.001_bb1120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045259","article-title":"Use of fibrates and Cancer risk: a systematic review and meta-analysis of 17 long-TermRandomized placebo-controlled trials","volume":"7","author":"Bonovas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.plipres.2018.06.001_bb1125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0895-4356(98)00147-4","article-title":"Lipid-lowering medication and risk of cancer","volume":"52","author":"Olsen","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjcard.2008.09.092","article-title":"Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort)","volume":"103","author":"Gardette","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1135","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.325.7378.1437","article-title":"Data dredging, bias, or confounding","volume":"325","author":"Davey Smith","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.plipres.2018.06.001_bb1140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2796.1994.tb01029.x","article-title":"The Helsinki Heart Study: an 8.5 year safety and mortality follow-up","volume":"235","author":"Huttunen","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1155","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"FIELD Study Investigators, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.plipres.2018.06.001_bb1160","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1165","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in coronary drug project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1175","first-page":"5","article-title":"Anacetrapib, a new CETP inhibitor: the new tool for the management of dyslipidemias?","volume":"29","author":"Filippatos","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/j.plipres.2018.06.001_bb1180","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1185","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1190","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1195","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plipres.2018.06.001_bb1200","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.phrs.2017.02.008","article-title":"Effects of curcumin on HDL functionality","volume":"119","author":"Ganjali","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb1205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.numecd.2016.11.122","article-title":"Joint position statement on \"nutraceuticals for the treatment of hypercholesterolemia\" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of arteriosclerosis (SISA)","volume":"27","author":"Pirro","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.plipres.2018.06.001_bb1210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/112_2016_3","article-title":"Curcumin as a MicroRNA regulator in cancer: a review","volume":"171","author":"Momtazi","year":"2016","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.plipres.2018.06.001_bb1215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/biof.1344","article-title":"Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: a review of chemistry, cellular, molecular, and preclinical features","volume":"43","author":"Teymouri","year":"2017","journal-title":"Biofactors"},{"key":"10.1016\/j.plipres.2018.06.001_bb1220","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.7150\/jca.19106","article-title":"Berberine enhances chemosensitivity and induces apoptosis through dose-orchestrated AMPK signaling in breast cancer","volume":"8","author":"Pan","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.plipres.2018.06.001_bb1225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-319-16555-4_6","article-title":"Synthetic high-density lipoprotein-like nanoparticles as cancer therapy","volume":"166","author":"McMahon","year":"2015","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.plipres.2018.06.001_bb1230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7150\/thno.6617","article-title":"Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles","volume":"3","author":"Zheng","year":"2013","journal-title":"Theranostics"}],"container-title":["Progress in Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782718300079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163782718300079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:42:07Z","timestamp":1759012927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163782718300079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":246,"alternative-id":["S0163782718300079"],"URL":"https:\/\/doi.org\/10.1016\/j.plipres.2018.06.001","relation":{},"ISSN":["0163-7827"],"issn-type":[{"value":"0163-7827","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High density lipoprotein cholesterol and cancer: Marker or causative?","name":"articletitle","label":"Article Title"},{"value":"Progress in Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plipres.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}